Consensus statements from international specialty colleges
Cross-jurisdictional guideline comparison between NICE (UK), ACC/AHA (US), and ESC (Europe) with Class & Level of Evidence badges.
| Clinical Question / Decision Point | NICE (United Kingdom) | ACC / AHA (United States) | ESC (Europe) |
|---|---|---|---|
| Hypertension Diagnostic Threshold | >= 140/90 mmHg Confirmed by ABPM / HBPM (>= 135/85) | >= 130/80 mmHg Stage 1 HTN defined earlier | >= 140/90 mmHg Home monitoring confirmed |
| Heart Failure HFrEF Quadruple Therapy |
Class I ARNI + Beta-blocker + MRA + SGLT2i |
Class I, Level A All 4 foundation pillars initiated early |
Class I, Level A Universal 4-pillar GDMT recommendation |
| Atrial Fibrillation Anticoagulation | CHA2DS2-VASc >= 2 Prefer DOAC over Warfarin | CHA2DS2-VASc >= 2 (M) / 3 (F) DOACs first-line recommendation | CHA2DS2-VASc >= 2 (M) / 3 (F) Consider if score 1 in men / 2 in women |
Comparison of Stage 1/2 cutoffs, ABPM confirmation, and first-line drug selection
ACC/AHA defines hypertension at >= 130/80 mmHg; NICE maintains traditional threshold at >= 140/90 mmHg confirmed by ABPM/HBPM.
The Medstufise reference engines provide peer-reviewed summaries for healthcare professionals and medical trainees. Always correlate clinical calculators, algorithms, and dosing tables with bedside clinical signs, patient-specific renal/hepatic parameters, and local NHS Trust hospital protocols.
Jump directly into another verified medical knowledge engine:
